Az emlőrák szisztémás kezelése: szakmai útmutatás

The article presents the practice guideline of systemic treatment of breast cancer and recommendations of the 3rd Hungarian Breast Cancer Consensus Conference. It reflects the recent international guidelines (ESMO, NCCN, ABC2, St Gallen's) irrespectively of the current financial opportunities. Here we follow the early - locally advanced - locally relapsed - metastatic breast cancer line for didactic considerations and we discuss the different subgroups of breast cancer based on hormone receptor and HER2 receptor status. Diagnosis and treatment options of rare clinical entities are summarised at the end of the paper

A Rare but Real Entity: Bladder Neuroendocrine Cancer

The neuoroendocrine cancer of the bladder is a rare tumour, and from this entity the well-differentiated tumours with favourable prognosis, the paraganglioma with unfavourable prognosis, small and large cell types of tumours should be emphasised. From the methods of the anticancer therapies’ operation can be eligible by itself in the first group but in the second group should form only the part of the multimodal treatment. Radiotherapy plays a role only in the treatment of the small and large cell tumours, and during the treatment of these tumours, the administration of the cytostatic drugs is also essential (mainly platina derivates). Somatostatin analogues, immune checkpoint inhibitors could be beneficial in special cases and some tumour agnostic treatment can be useful as well. Moreover, the palliative treatment should represent an important modality even in the early treatment period, but it should also be provided when no other treatment options are left

Az emlőrák szisztémás kezelése: szakmai útmutatás

The article presents the practice guideline of systemic treatment of breast cancer and recommendations of the 3rd Hungarian Breast Cancer Consensus Conference. It reflects the recent international guidelines (ESMO, NCCN, ABC2, St Gallen's) irrespectively of the current financial opportunities. Here we follow the early - locally advanced - locally relapsed - metastatic breast cancer line for didactic considerations and we discuss the different subgroups of breast cancer based on hormone receptor and HER2 receptor status. Diagnosis and treatment options of rare clinical entities are summarised at the end of the paper

Az emlőrák szisztémás kezelése: szakmai útmutatás

K